Alpha-Mannosidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Alpha-mannosidosis is an autosomal recessive lysosomal storage disease caused by MAN2B1 gene mutations. It is diagnosed by detecting low levels of acidic alpha-mannosidase enzyme activity in peripheral blood leukocytes or cultured skin fibroblasts, with affected individuals displaying 5–15% of regular leukocyte activity. In most patients, the disease is clinically recognised in the first decade of life, progression is slow, and ataxia develops between 20 to 30 years. Long-term enzyme replacement therapy (ERT) is a treatment option for alpha-mannosidosis, and the first human recombinant form of alpha-mannosidase available for ERT is velmanase alfa. Patients with alpha-mannosidosis who were treated with velmanase alfa improved in biomarkers, motor function, pulmonary function, immunologic profile, and quality of life in clinical trials. Intracellular accumulation of mannose-rich oligosaccharides causes various clinical symptoms, including hearing loss, intellectual disabilities, and motor function and speech impairment.

  • The prevalence of Alpha-mannosidosis ranges from 1 to 2 cases per 500,000 live birth in the USA.

Thelansis’s “Alpha-Mannosidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alpha-Mannosidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Alpha-Mannosidosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Alpha-Mannosidosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Alpha-Mannosidosis– Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033